Loading clinical trials...
Loading clinical trials...
A Study of Olverembatinib in the Treatment of Myeloid/Lymphoid Tumors With FGFR1 Rearrangement
Conditions
Interventions
Olverembatinib
Locations
1
China
First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Start Date
September 1, 2022
Primary Completion Date
August 31, 2024
Completion Date
August 31, 2027
Last Updated
August 30, 2022
NCT05564390
NCT03050268
NCT07216443
NCT07295951
NCT04726241
NCT05735717
Lead Sponsor
The First Affiliated Hospital of Soochow University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions